Foundayo wins its first European approval

Eli Lilly's weight-loss pill, sold as Foundayo and known by its molecule name orforglipron, has won its first approval in Europe. The U.K.'s Medicines and Healthcare products Regulatory Agency cleared the drug on Monday, August 11, for weight management and type 2 diabetes, making it only the second GLP-1 weight-loss pill approved in the region ^[1].

The approval comes about two months after Novo Nordisk launched its own Wegovy pill in the U.K. ^[1]. Both drugs are oral GLP-1 medicines, but they work differently. Wegovy pill uses semaglutide, the same active ingredient found in the injectable Wegovy and Ozempic. Foundayo uses orforglipron, a small-molecule drug that Lilly says can be taken without food restrictions. Wegovy's pill, by contrast, must be taken first thing in the morning with only a sip of water, followed by at least 30 minutes with no other food or drink ^[1].

Foundayo's U.K. rollout will start on a private-prescription basis. For it to become available through the National Health Service, it still needs a cost-effectiveness review from the National Institute for Health and Care Excellence ^[1]. That process determines whether the NHS will pay for the drug on a broad scale, separate from the initial regulatory approval.

In the U.S., where Foundayo launched in April, the drug has moved more slowly than Novo's pill. Lilly CEO David Ricks told CNBC in April that this was because Foundayo is a completely new medicine that needs time to build familiarity with doctors and patients, unlike Wegovy pill, which shares its active ingredient with already-established injectable products ^[1]. Foundayo brought in $98 million in U.S. sales in the second quarter of 2026 ^[1]. Meanwhile, Novo Nordisk CEO Mike Doustdar said about 300,000 patients in the U.K. were estimated to have started on the Wegovy pill within its first three weeks on the market there ^[1].

Why it matters for patients

For patients in the U.K., Foundayo's approval means a second oral GLP-1 option is now on the table, alongside Wegovy pill, though for now it will only be available by private prescription while the NHS reviews its cost-effectiveness ^[1]. That review will shape whether cost becomes a barrier for many patients seeking the drug through public health coverage.

The difference in food rules between the two pills could matter for day-to-day routines. Wegovy pill requires a strict fasting window each morning, while Lilly says Foundayo does not carry the same restriction ^[1]. Patients weighing oral options may find that difference relevant to how the medicine fits into daily life, though the sources do not compare the two drugs' effectiveness or side effects directly.

Both companies describe the pill market as still developing. Novo's CEO said he sees a future where pills make up a large share of the GLP-1 market, while cautioning it remains early days for Wegovy pill ^[1]. Slower early U.S. uptake for Foundayo, according to Lilly's own explanation, reflects the time it takes for a genuinely new medicine to become familiar to prescribers and patients, separate from questions about the drug's underlying safety or effectiveness ^[1].

What happens next

Foundayo's path onto the NHS in the U.K. depends on the outcome of the National Institute for Health and Care Excellence's cost-effectiveness review, which has not yet concluded ^[1]. The article notes Foundayo's U.K. approval was corrected on August 11, 2026, to clarify it was the drug's first approval anywhere in Europe, suggesting other European regulatory decisions may follow but are not yet detailed in the sources ^[1].